B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

MAPK1

MOLECULAR TARGET

mitogen-activated protein kinase 1

UniProt: P28482NCBI Gene: 559422 compounds

MAPK1 (mitogen-activated protein kinase 1) is targeted by 22 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MAPK1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1plumbagin [Supplementary Concept]2.5612
2pd980591.956
3tyrphostin ag 14781.795
4alsterpaullone1.393
5kenpaullone1.393
6Clotrimazole1.102
7sp6001251.102
8fisetin0.691
9Progesterone0.691
102-Chloroadenosine 2-Chloroadenosine.0.691
11Benzalkonium Compounds0.691
12Calcimycin0.691
13daph0.691
14Diphenhydramine0.691
15ha10040.691
16isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside [Supplementary Concept] from0.691
17Lithocholic Acid0.691
18Loratadine0.691
19Sorafenib0.691
20trametinib0.691
21trequinsin hydrochloride0.691
22withaferin0.691

About MAPK1 as a Drug Target

MAPK1 (mitogen-activated protein kinase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 22 compounds with documented MAPK1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MAPK1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.